How Does CBG Administration Affect Sphingolipid Deposition in the Liver of Insulin-Resistant Rats?
cannabigerol
ceramide
insulin resistance
liver
metabolic disorders
sphingolipid metabolism
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
received:
08
09
2023
revised:
03
10
2023
accepted:
10
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Cannabigerol (CBG), a non-psychotropic phytocannabinoid found in In a rat model of insulin resistance induced by a high-fat, high-sucrose diet (HFHS), we aimed to elucidate the effect of intragastrically administered CBG on hepatic sphingolipid deposition and metabolism. Moreover, we also elucidated the expression of sphingolipid transporters and changes in the sphingolipid concentration in the plasma. The results, surprisingly, showed a lack of changes in de novo ceramide synthesis pathway enzymes and significant enhancement in the expression of enzymes involved in ceramide catabolism, which was confirmed by changes in hepatic sphingomyelin, sphinganine, sphingosine-1-phosphate, and sphinganine-1-phosphate concentrations. The results suggest that CBG treatment may modulate sphingolipid metabolism in the liver and plasma, potentially protecting the liver against the development of metabolic disorders such as insulin resistance.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabigerol (CBG), a non-psychotropic phytocannabinoid found in
METHODS
METHODS
In a rat model of insulin resistance induced by a high-fat, high-sucrose diet (HFHS), we aimed to elucidate the effect of intragastrically administered CBG on hepatic sphingolipid deposition and metabolism. Moreover, we also elucidated the expression of sphingolipid transporters and changes in the sphingolipid concentration in the plasma.
RESULTS
RESULTS
The results, surprisingly, showed a lack of changes in de novo ceramide synthesis pathway enzymes and significant enhancement in the expression of enzymes involved in ceramide catabolism, which was confirmed by changes in hepatic sphingomyelin, sphinganine, sphingosine-1-phosphate, and sphinganine-1-phosphate concentrations.
CONCLUSIONS
CONCLUSIONS
The results suggest that CBG treatment may modulate sphingolipid metabolism in the liver and plasma, potentially protecting the liver against the development of metabolic disorders such as insulin resistance.
Identifiants
pubmed: 37892425
pii: nu15204350
doi: 10.3390/nu15204350
pmc: PMC10609522
pii:
doi:
Substances chimiques
Sphingolipids
0
Insulin
0
safingol
OWA98U788S
Ceramides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Minister of Education and Science from the state budget under the program "Student science clubs create innovations"
ID : SKN/SP/534956/2022
Organisme : Medical University of Białystok
ID : B.SUB.23.321
Références
Biomolecules. 2021 Feb 12;11(2):
pubmed: 33673122
Acta Physiol (Oxf). 2008 Apr;192(4):519-29
pubmed: 17970831
Biomed Pharmacother. 2022 Sep;153:113341
pubmed: 35785704
Endocrinol Metab Clin North Am. 2008 Dec;37(4):841-56
pubmed: 19026935
Nutr Diabetes. 2013 May 27;3:e68
pubmed: 23712280
Mediators Inflamm. 2015;2015:520618
pubmed: 26648664
Front Pharmacol. 2018 Jun 21;9:632
pubmed: 29977202
J Biol Chem. 2005 Jul 29;280(30):27879-87
pubmed: 15946935
PLoS One. 2011;6(6):e21041
pubmed: 21695082
J Clin Med. 2023 Jul 11;12(14):
pubmed: 37510734
Food Funct. 2016 Sep 14;7(9):3981-3988
pubmed: 27722538
Hepatology. 2006 Nov;44(5):1278-87
pubmed: 17058266
J Hepatol. 2016 Jan;64(1):60-8
pubmed: 26254847
Int J Mol Sci. 2019 Nov 24;20(23):
pubmed: 31771303
PLoS One. 2015 Jan 30;10(1):e0116858
pubmed: 25635851
Front Physiol. 2020 Jul 07;11:732
pubmed: 32733268
Science. 2019 Oct 18;366(6463):
pubmed: 31624181
Front Endocrinol (Lausanne). 2019 Aug 21;10:577
pubmed: 31496996
Biomed Pharmacother. 2021 Oct;142:112057
pubmed: 34435590
Prog Chem Org Nat Prod. 2017;103:61-101
pubmed: 28120231
Toxicol Sci. 2017 Sep 1;159(1):159-169
pubmed: 28903485
J Neuroimmune Pharmacol. 2012 Dec;7(4):1002-16
pubmed: 22971837
Physiol Rep. 2020 Oct;8(19):e14607
pubmed: 33038072
Evid Based Complement Alternat Med. 2022 Nov 8;2022:3336516
pubmed: 36397993
Behav Pharmacol. 2012 Sep;23(5-6):526-36
pubmed: 22785439
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
Thromb Haemost. 2018 Jun;118(6):1021-1035
pubmed: 29669385
Hepatology. 2014 Jan;59(1):143-53
pubmed: 23832510
Adv Exp Med Biol. 2010;688:1-23
pubmed: 20919643
Biochim Biophys Acta. 2013 Dec;1832(12):1922-9
pubmed: 23816565
Biomedicines. 2023 Jan 21;11(2):
pubmed: 36830844
Nutrients. 2021 May 11;13(5):
pubmed: 34064937
Anal Biochem. 2013 Sep 15;440(2):186-8
pubmed: 23747530
Int J Mol Sci. 2022 Feb 17;23(4):
pubmed: 35216351
Int J Mol Sci. 2022 May 11;23(10):
pubmed: 35628194
J Pharmacol Exp Ther. 2021 Feb;376(2):204-212
pubmed: 33168643
Biochem Pharmacol. 2013 May 1;85(9):1306-16
pubmed: 23415610
J Hepatol. 2004 Jan;40(1):47-51
pubmed: 14672613
Biomolecules. 2020 Aug 26;10(9):
pubmed: 32859125
Signal Transduct Target Ther. 2022 Jul 6;7(1):216
pubmed: 35794109
J Ethnopharmacol. 2018 Dec 5;227:300-315
pubmed: 30205181
Biochim Biophys Acta. 2013 Nov;1833(11):2511-8
pubmed: 23611790
Sci Rep. 2016 Aug 26;6:32119
pubmed: 27562371
BMC Endocr Disord. 2020 Jun 10;20(1):85
pubmed: 32522257
Life Sci. 2005 Dec 22;78(5):539-48
pubmed: 16199061
Int J Mol Sci. 2018 Mar 03;19(3):
pubmed: 29510489
Adv Exp Med Biol. 2017;960:277-304
pubmed: 28585204
Eur J Histochem. 2017 Jan 23;61(1):2749
pubmed: 28348416